Zymeworks secures $250M non-recourse royalty-backed note from Royalty Pharma on Ziihera royalties

This filing

Following the sale and transfer of the Royalty Interest, the Subsidiary entered into a Loan Agreement (the “ Loan Agreement ”), dated March 2, 2026, with Royalty Pharma as administrative agent and lender (in the capacity as lender under the Loan Agreement, the “ Lender ” and together with such other lenders party to the Loan Agreement from time to time the “ Lenders ”), pursuant to which the Lenders made a term loan to the Subsidiary (the “ Loan ”) in an aggregate principal amount of $250.0 million (the “ Loan Amount ”), that bears interest at a fixed rate and matures on December 31, 2042 (the “ Maturity Date ”).

Comparable filing

The first Convertible Debenture (the “First Debenture”) in the principal amount of $20,000,000 was issued on May 7, 2026.

This filing

Following the sale and transfer of the Royalty Interest, the Subsidiary entered into a Loan Agreement (the “ Loan Agreement ”), dated March 2, 2026, with Royalty Pharma as administrative agent and lender (in the capacity as lender under the Loan Agreement, the “ Lender ” and together with such other lenders party to the Loan Agreement from time to time the “ Lenders ”), pursuant to which the Lenders made a term loan to the Subsidiary (the “ Loan ”) in an aggregate principal amount of $250.0 million (the “ Loan Amount ”), that bears interest at a fixed rate and matures on December 31, 2042 (the “ Maturity Date ”).

Comparable filing

specified in the Exchange Agreement on the terms and subject to the conditions set forth therein. The consideration under the Exchange Agreement consists of (i) a new $150.0 million term loan facility held by the Participating Lenders (the “Priority Term Loans”), (ii) the issuance of 39,250 shares of Series A Cumulative Convertible Preferred Stock (the

This filing

Following the sale and transfer of the Royalty Interest, the Subsidiary entered into a Loan Agreement (the “ Loan Agreement ”), dated March 2, 2026, with Royalty Pharma as administrative agent and lender (in the capacity as lender under the Loan Agreement, the “ Lender ” and together with such other lenders party to the Loan Agreement from time to time the “ Lenders ”), pursuant to which the Lenders made a term loan to the Subsidiary (the “ Loan ”) in an aggregate principal amount of $250.0 million (the “ Loan Amount ”), that bears interest at a fixed rate and matures on December 31, 2042 (the “ Maturity Date ”).

Comparable filing

Stanley Bank, N.A., Bank of America, N.A., Bank of Montreal and UBS AG New York Branch, or collectively, the lenders, pursuant to which Mountain JV obtained, in aggregate, a $1.62 billion loan secured by 90 of its properties, or the Loan . Also on May 8, 2026, we entered into a guaranty in favor of the lenders, pursuant to which we guaranteed certain limited

This filing

Following the sale and transfer of the Royalty Interest, the Subsidiary entered into a Loan Agreement (the “ Loan Agreement ”), dated March 2, 2026, with Royalty Pharma as administrative agent and lender (in the capacity as lender under the Loan Agreement, the “ Lender ” and together with such other lenders party to the Loan Agreement from time to time the “ Lenders ”), pursuant to which the Lenders made a term loan to the Subsidiary (the “ Loan ”) in an aggregate principal amount of $250.0 million (the “ Loan Amount ”), that bears interest at a fixed rate and matures on December 31, 2042 (the “ Maturity Date ”).

Comparable filing

The issuance of the Notes in the aggregate original principal amount of $2,500,000 constitutes the creation of a direct financial obligation of the Company. The Notes bear interest at 12.0% per annum, mature on February 4, 2027

This filing

Following the sale and transfer of the Royalty Interest, the Subsidiary entered into a Loan Agreement (the “ Loan Agreement ”), dated March 2, 2026, with Royalty Pharma as administrative agent and lender (in the capacity as lender under the Loan Agreement, the “ Lender ” and together with such other lenders party to the Loan Agreement from time to time the “ Lenders ”), pursuant to which the Lenders made a term loan to the Subsidiary (the “ Loan ”) in an aggregate principal amount of $250.0 million (the “ Loan Amount ”), that bears interest at a fixed rate and matures on December 31, 2042 (the “ Maturity Date ”).

Comparable filing

On May 8, 2026, Knight-Swift Transportation Holdings Inc. (the "Company") completed its previously announced private offering (the "Offering") of $1.5 billion aggregate principal amount of 1.00% Convertible Senior Notes due 2031

This filing

On March 2, 2026, Zymeworks BC Inc. (“ Zymeworks BC ”), a subsidiary of Zymeworks Inc. (the “ Company ”), entered into a sale agreement (the “ Sale Agreement ”) with Zymeworks Royalty Limited Partnership (the “ Subsidiary ”), a special purpose entity newly formed by Zymeworks BC and by its general partner Zymeworks General Partner ULC (“ Zymeworks GP ”), the Company solely for the purpose of certain indemnification provisions thereunder, and Royalty Pharma Development Funding, LLC (“ Royalty Pharma ”) as administrative agent.

Comparable filing

Concurrently with the Notes offering, the Issuer refinanced its existing senior secured dollar-denominated term loan facility due 2030 (the “ 2030 Term Loan Facility ”) with a new senior secured dollar-denominated term loan facility in an aggregate principal amount of approximately $2,750.0 million (the “ 2033 Refinancing Term Loan Facility ” and, together with the existing revolving credit facility, the “ Senior Secured Credit Facilities ”).

This filing

On March 2, 2026, Zymeworks BC Inc. (“ Zymeworks BC ”), a subsidiary of Zymeworks Inc. (the “ Company ”), entered into a sale agreement (the “ Sale Agreement ”) with Zymeworks Royalty Limited Partnership (the “ Subsidiary ”), a special purpose entity newly formed by Zymeworks BC and by its general partner Zymeworks General Partner ULC (“ Zymeworks GP ”), the Company solely for the purpose of certain indemnification provisions thereunder, and Royalty Pharma Development Funding, LLC (“ Royalty Pharma ”) as administrative agent.

Comparable filing

On May 28, 2026, the Company, as parent, Trinseo NA Finance LLC, as holdings, Trinseo Luxco Finance SPV S.à r.l. and Trinseo NA Finance SPV LLC (together, the “ SHC Borrowers ”), as borrowers, the guarantors party thereto from time to time, the lenders party thereto from time to time (the “ SHC DIP Lenders ”), and Alter Domus (US) LLC, as administrative agent and collateral agent, entered into a Senior Secured Super-Priority Debtor-In-Possession HoldCo Credit Agreement (the “ Super-Holdco DIP Credit Agreement ”), providing for a senior secured super-priority priming term loan debtor-in-possession credit facility in an aggregate principal amount of $157.5 million (the “ Super-Holdco DIP Facility ”).

This filing

Following the sale and transfer of the Royalty Interest, the Subsidiary entered into a Loan Agreement (the “ Loan Agreement ”), dated March 2, 2026, with Royalty Pharma as administrative agent and lender (in the capacity as lender under the Loan Agreement, the “ Lender ” and together with such other lenders party to the Loan Agreement from time to time the “ Lenders ”), pursuant to which the Lenders made a term loan to the Subsidiary (the “ Loan ”) in an aggregate principal amount of $250.0 million (the “ Loan Amount ”), that bears interest at a fixed rate and matures on December 31, 2042 (the “ Maturity Date ”).

Comparable filing

CONMED entered into the First Amendment to, among other things, obtain commitments for incremental senior secured delayed draw term “a” loans available in U.S. dollars to CONMED in an aggregate principal amount equal to $450 million (the “ Term A-2 Loan Facility ”), which is available to be borrowed in a single drawing on or prior to June 14, 2026.